Immunitybio, Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Product at $50.7 million, 99% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
166
|
51
|
44
|
38
|
32
|
26
|
17
|
8
|
6
|
| Product |
165
+194.0%
share 99.5%
|
51
+91.8%
share 98.9%
|
44
+167.5%
share 99.9%
|
38
+431.1%
share 100.0%
|
32
+433.8%
share 99.1%
|
26
share 100.0%
|
17
share 100.0%
|
7
share 95.4%
|
6
share 97.5%
|
| Product And Service Other |
1
+76.7%
share 0.5%
|
1
+14100.0%
share 1.1%
|
0
+387.5%
share 0.1%
|
0
-96.2%
share 0.0%
|
0
+84.9%
share 0.9%
|
0
share 0.0%
|
0
share 0.0%
|
0
share 4.6%
|
0
share 2.5%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1326110
- Former names
- NantKwest, Inc. (until Mar 8, 2021); Conkwest, Inc. (until Jul 13, 2015); ZelleRx Corp (until Oct 9, 2009)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.